Evidence map›Paper›PMID 37396570›Full record

ArticleClinical and translational discovery2022

Chromium (VI) promotes lung cancer initiation by activating EGF/ALDH1A1 signalling.

Anastasia E Metropulos, Jeffrey H Becker, Daniel R Principe

Open access · goldAbstract readComment
In one paragraph

Article in Clinical and translational discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Anastasia E MetropulosFeinberg School of Medicine, Northwestern University, Chicago IL USA.
Jeffrey H BeckerDepartment of Surgery, University of Illinois at Chicago, Chicago, IL USA.
Daniel R PrincipeMedical Scientist Training Program, University of Illinois College of Medicine, Chicago, IL USA.
Illinois College · USNorthwestern University · USUniversity of Illinois Chicago · US

Funding

Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway InhibitionF30CA236031 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PRINCIPE, DANIEL R · 2019 to 2023
$256k
NCI NIH HHS F30 CA236031
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer-related death worldwide and is strongly associated with tobacco smoke exposure. Though smoking remains the most important and best studied risk factor, recent data suggests that several other carcinogens have a driving role in lung cancer development, particularly in select populations at risk of high or prolonged exposure. Hexavalent chromium [Cr(VI)] is a known carcinogen that is widely used in the manufacturing industry. While the link between Cr(VI) and lung cancer incidence is well-accepted, the mechanisms through which Cr(VI) promotes lung cancer development are poorly understood. In the present study by Ge and colleagues published in

Indexed as

ALDH1A1Cancer Stem CellsCarcinogensEGFHexavalent ChromiumLung CancerTumor Initiation

Identifiers

PMID37396570
PMCPMC10312984
OpenAlexW4311507687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.